Serious adverse events reported in placebo randomised controlled trials of oral naltrexone: a systematic review and meta-analysis.
| Author | |
|---|---|
| Abstract |
:
Naltrexone is an opioid antagonist used in many different conditions, both licensed and unlicensed. It is used at widely varying doses from 3 to 250 mg. The aim of this review was to extensively evaluate the safety of oral naltrexone by examining the risk of serious adverse events and adverse events in randomised controlled trials of naltrexone compared to placebo. |
| Year of Publication |
:
2019
|
| Journal |
:
BMC medicine
|
| Volume |
:
17
|
| Issue |
:
1
|
| Number of Pages |
:
10
|
| Date Published |
:
2019
|
| URL |
:
https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-018-1242-0
|
| DOI |
:
10.1186/s12916-018-1242-0
|
| Short Title |
:
BMC Med
|
| Download citation |
